Background: Recent frameworks for understanding food rewards recognize the role of separable affective and motivational processes (liking and wanting) in driving human eating behavior. Separate assessments of liking and wanting may aid in understanding the complex eating-related behaviors seen in anorexia nervosa (AN).
Objective: The aim of this study was to examine separately liking and wanting for foods of different energy densities in women at different stages of AN and in healthy volunteers at both an implicit and an explicit level.
Design: Explicit liking and wanting responses to high- and low-calorie foods were derived from analog ratings, whereas an implicit "wanting" measure was identified by using reaction time in a forced-choice procedure. Explicit and implicit processes were compared across 3 groups of AN participants (current AN, weight-restored AN, and recovered AN) and healthy volunteers.
Results: Currently underweight AN participants explicitly wanted high-calorie foods less than did the other groups. Both current and weight-restored AN groups demonstrated significantly less implicit "wanting" for high-calorie foods and more implicit "wanting" for low-calorie foods-an inverted pattern to never-ill participants.
Conclusions: The aberrant responses to food that characterize AN may be driven more by altered motivational salience ("wanting") than by explicit liking responses. This pattern of aberrant food reward appears to be independent of weight status. Examining the processes that motivate approach or avoidance of low- and high-calorie foods in AN may aid the development of targeted strategies to augment existing interventions.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3945/ajcn.112.046011 | DOI Listing |
Curr Opin Urol
December 2024
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Purpose Of Review: Men face distinctive health-related challenges as a result of biological, behavioral, and sociocultural factors. In addition, the modern healthcare system does not offer men equal opportunities and options to ensure sex-specific access and delivery to health services. Men's health concerns are, indeed, often not addressed or even forgotten.
View Article and Find Full Text PDFInt J Med Inform
December 2024
School of Psychology, Deakin University, Burwood Campus, 221 Burwood Highway, Burwood VIC 3125, Australia. Electronic address:
Background: Many people with endometriosis want to learn more about their condition and connect with others for support. Frequently they turn to social media site Facebook to do so. This study aimed to explore the drivers of endometriosis consumers' intentions and use of Facebook for health-related information and support, as outlined in the Theory of Planned Behavior (TPB).
View Article and Find Full Text PDFPhys Ther Sport
December 2024
School of Healthcare Sciences, Cardiff University, CF14 4XN, Cardiff, UK. Electronic address:
Objectives: Explore digital technology use among recreational runners in Wales and assess attitudes toward a proposed digital intervention for running-related injury (RRI) prevention and self-management.
Design: Exploratory survey.
Setting: Online questionnaire, closed questions distributed to runners over a 7 week period.
Neuropsychopharmacology
December 2024
Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands.
3-Methylmethcathinone (3-MMC) is a designer drug that belongs to the group of synthetic cathinones. The compound has been scheduled in many jurisdictions because of public health concerns associated with excessive use. To date, there are no clinical studies that have evaluated the risk profile of 3-MMC in the recreational range of low to moderate doses.
View Article and Find Full Text PDFAm J Geriatr Psychiatry
November 2024
Department of Bioethics (CRM, SH, SYK), Clinical Center, National Institutes of Health Clinical Center, Bethesda, MD. Electronic address:
Objective: The new antiamyloid medications Lecanemab (Leqembi) and donanemab (Kisunla) are the first disease-modifying treatments for Alzheimer's disease (AD) to receive full FDA approval. However, some commentators question whether the drugs' benefits outweigh their risks, burdens, and costs to patients. This study assessed the perceived value of these medications by asking caregivers of persons with AD to compare them to a widely used intervention in AD management: home-based care.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!